|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Biomimetic Therapeutics, Inc. (BMTI) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
28,001,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
250,541 |
Avg
Vol: |
116,764 |
| 52
Week Range: |
$9.49 - $9.49 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ehrlich Christopher B |
Director |
– • – |
2013-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,250) |
0 |
|
- |
|
| Pagano Russell P. |
VP, Reg. & Clinical Affairs |
• – – |
2013-01-22 |
4 |
AS |
$8.10 |
$11,187 |
D/D |
(1,381) |
6,716 |
|
- |
|
| Friedlaender Gary E |
Director |
– • – |
2012-04-02 |
4 |
B |
$2.79 |
$27,923 |
D/D |
10,000 |
43,995 |
2.39 |
- |
|
| Lynch Samuel Eugene |
President and CEO |
• • – |
2012-03-30 |
4 |
B |
$2.40 |
$95,632 |
D/D |
39,362 |
1,239,391 |
2.81 |
- |
|
| Pagano Russell P. |
VP, Reg. & Clinical Affairs |
• – – |
2012-03-29 |
4 |
AS |
$2.36 |
$8,128 |
D/D |
(3,438) |
5,996 |
|
- |
|
| Lynch Samuel Eugene |
President and CEO |
• • – |
2012-03-29 |
4 |
B |
$2.38 |
$72,891 |
D/D |
30,638 |
1,200,029 |
2.81 |
- |
|
| Douglas Earl Martin |
General Counsel |
• – – |
2012-03-28 |
4 |
S |
$2.32 |
$111,772 |
D/D |
(47,461) |
11,056 |
|
- |
|
| Papasan Larry W |
Director |
– • – |
2012-03-27 |
4 |
B |
$2.32 |
$24,147 |
D/D |
10,400 |
30,781 |
2.39 |
- |
|
| Douglas Earl Martin |
General Counsel |
• – – |
2012-03-27 |
4 |
S |
$2.34 |
$11,700 |
D/D |
(5,000) |
58,517 |
|
- |
|
| Douglas Earl Martin |
General Counsel |
• – – |
2012-03-26 |
4 |
S |
$2.35 |
$2,585 |
D/D |
(1,100) |
63,517 |
|
- |
|
| Lynch Samuel Eugene |
President and CEO |
• • – |
2012-03-23 |
4 |
B |
$2.35 |
$1,058 |
I/I |
450 |
5,550 |
2.58 |
- |
|
| Lynch Samuel Eugene |
President and CEO |
• • – |
2012-03-23 |
4 |
B |
$2.35 |
$29,845 |
D/D |
12,700 |
1,169,391 |
2.81 |
- |
|
| Bullock Lawrence E |
Chief Financial Officer |
• – – |
2012-03-20 |
4 |
B |
$2.20 |
$38,874 |
D/D |
17,670 |
78,723 |
2.74 |
- |
|
| Lynch Samuel Eugene |
President and CEO |
• • – |
2012-03-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(42,269) |
0 |
|
- |
|
| Lynch Samuel Eugene |
President and CEO |
• • – |
2012-03-20 |
4 |
GD |
$0.00 |
$0 |
I/I |
100,000 |
42,269 |
|
- |
|
| Lynch Samuel Eugene |
President and CEO |
• • – |
2012-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
42,269 |
1,156,691 |
|
- |
|
| Lynch Samuel Eugene |
President and CEO |
• • – |
2012-03-20 |
4 |
GA |
$0.00 |
$0 |
D/D |
100,000 |
1,114,422 |
|
- |
|
| Friedlaender Gary E |
Director |
– • – |
2012-03-19 |
4 |
B |
$2.18 |
$21,869 |
I/I |
10,000 |
11,762 |
2.1 |
- |
|
| Friedlaender Gary E |
Director |
– • – |
2012-03-19 |
4 |
B |
$2.20 |
$10,984 |
D/D |
5,000 |
33,995 |
2.39 |
- |
|
| Bullock Lawrence E |
Chief Financial Officer |
• – – |
2012-03-19 |
4 |
B |
$2.20 |
$5,126 |
D/D |
2,330 |
61,053 |
2.74 |
- |
|
| Lynch Samuel Eugene |
President and CEO |
• • – |
2011-11-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
112,072 |
142,269 |
|
- |
|
| Lynch Samuel Eugene |
President and CEO |
• • – |
2011-11-16 |
4 |
GA |
$0.00 |
$0 |
D/D |
112,072 |
1,014,422 |
|
- |
|
| Bullock Lawrence E |
Chief Financial Officer |
• – – |
2011-10-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
16,000 |
28,000 |
|
- |
|
| Bullock Lawrence E |
Chief Financial Officer |
• – – |
2011-10-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
16,000 |
58,723 |
|
- |
|
| Douglas Earl Martin |
General Counsel |
• – – |
2011-10-11 |
4 |
AS |
$3.01 |
$9,016 |
D/D |
(3,000) |
66,144 |
|
- |
|
230 Records found
|
|
Page 2 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
